跳至主要内容
临床试验/NCT03003130
NCT03003130已完成不适用

A Randomized, Multi-center, Evaluator-blinded Study to Evaluate the Efficacy and Safety of Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds

Galderma R&D1 个研究点 分布在 1 个国家目标入组 175 人开始时间: 2017年1月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Galderma R&D
入组人数
175
试验地点
1
主要终点
Percentage of Responders, Defined by at Least 1-point Improvement From Baseline on the WSRS.

研究概览

简要总结

This is a randomized, split face, multicenter study to evaluate the efficacy and safety of Restylane Defyne compared to Restylane in correction of NLFs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Signed informed consent.
  • •Men or women aged 18 years of age or older of Chinese origin.
  • •Subjects willing to abstain from any other facial plastic surgical or cosmetic procedures below the level of the lower orbital rim for the duration of the study.
  • •Intent to undergo correction of both NLFs with a wrinkle severity in WSRS of either 3 on both sides or 4 on both sides, as assessed by the blinded evaluator.

排除标准

  • •Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) Gel and/or local anesthetics, e.g., lidocaine or other amide-type anesthetics.
  • •Previous tissue revitalization treatment below the level of the lower orbital rim within 6 months before treatment.
  • •Previous surgery or tattoo in the area to be treated.
  • •Previous tissue augmentation therapy or contouring with any permanent (nonbiodegradable) or semi-permanent facial tissue augmentation therapy or autologous fat or permanent implant below the level of the lower orbital rim.
  • •Previous use of neurotoxins or any hyaluronic acid based or collagen based biodegradable facial tissue augmentation therapy below the level of the lower orbital rim within 12 months before treatment.
  • •Scars or deformities, active skin disease, inflammation or related conditions such as infection, perioral dermatitis, seborrheic dermatitis, eczema, rosacea, acne, psoriasis, and herpes zoster near or in the area to be treated.
  • •Other condition preventing the subject from entering the study in the Investigator's opinion

研究组 & 干预措施

Restylane Defyne

Experimental

Single injection and optional touch up injection with Restylane Defyne in NLF

干预措施: Restylane Defyne (Device)

Restylane

Active Comparator

Single injection and optional touch up injection with Restylane in NLF

干预措施: Restylane (Device)

结局指标

主要结局

Percentage of Responders, Defined by at Least 1-point Improvement From Baseline on the WSRS.

时间窗: 6 month

The Wrinkle Severity Rating Scale (WSRS) is a validated photograph-based outcome instrument that is designed specifically for quantifying facial folds. Grade 1 Absent: No visible fold; continuous skin line Grade 2 Mild: Shallow but visible fold with a slight indentation; minor facial feature Implant is expected to produce a slight improvement in appearance Grade 3 Moderate: Moderately deep folds; clear facial feature visible at normal appearance but not when stretched. Excellent correction is expected from injectable implant Grade 4 Severe: Very long and deep fold; prominent facial feature; less than 2-mm visible fold when stretched Significant improvement is expected from injectable implant Grade 5 Extreme: Extremely deep and long fold; detrimental to facial appearance; 2- to 4-mm V-shaped fold when stretched. Unlikely to have satisfactory correction with injectable implant alone

次要结局

未报告次要终点

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验